secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001104659-24-038161
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee Therapeutics doses first volunteers in Phase 1 trial of APG808 for COPD and asthma
--------------------------------------------------------------------------------

- First participants dosed in Phase 1 healthy volunteer trial of APG808, a half-life extended IL-4Rα mAb.
- Preclinical data suggest potential for dosing every 6-8 weeks vs. every 2 weeks for other biologics in development.
- Interim safety and PK data from healthy volunteers anticipated in second half of 2024.
- APG808 is the second product candidate to enter clinic, following positive interim results from Phase 1 trial of APG777.
- Company plans to initiate Phase 1b asthma trial in 1H 2025 and Phase 2 COPD trial in 2025, pending positive Phase 1 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924038161/0001104659-24-038161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924038161/tm249632d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-038161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer